Infections, Streptococcal Clinical Trial
Official title:
An Exploratory Study in Healthy Elderly Subjects to Collect Urine for the Development of Assays to Detect Streptococcus Pneumoniae.
NCT number | NCT00523770 |
Other study ID # | BACDU-001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | August 30, 2007 |
Last updated | February 7, 2017 |
Start date | September 2007 |
Verified date | February 2017 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
GSK Biologicals is working on the development of a vaccine to protect elderly people from
pneumococcal infection. For the future studies in that project, it would be useful to have
some easy non invasive tests to detect infection by the bacteria. Some tests on urine are
already on the market but need to be improved in the laboratory. For that purpose, some
urine samples from healthy subjects aged 65 years or above and who have not suffered from
pneumonia nor have been administered pneumococcal vaccination in the past 3 months are
needed.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
2007
Status | Completed |
Enrollment | 50 |
Est. completion date | |
Est. primary completion date | September 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. - A male or female between, and including, 65 and 85 years of age at the time of the study. - Written informed consent obtained from the subject - Healthy subjects as established by medical history and clinical examination before entering into the study Exclusion Criteria: - Previous vaccination against Streptococcus pneumoniae in the 3 months before study start, - History of pneumonia confirmed by documented radiology or any other diagnostic method within 3 months prior to study start |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive or negative result using Binax NOW S. pneumoniae Test | within one day | ||
Secondary | Positive or negative result using the test to be developed for typing of S. pneumoniae | within one day | ||
Secondary | Positive or negative result using the test to be developed for detection of non-typable Haemophilus influenzae (NTHi) | within one day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01641133 -
Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
|
Phase 3 | |
Completed |
NCT01204658 -
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants
|
Phase 2 | |
Completed |
NCT00370396 -
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
|
Phase 3 | |
Completed |
NCT02838407 -
Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
|
N/A | |
Completed |
NCT00756067 -
Evaluation of Pneumococcal Vaccine Formulations in Elderly
|
Phase 1 | |
Completed |
NCT00345358 -
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT01153893 -
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria
|
Phase 3 | |
Completed |
NCT00307541 -
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT00547248 -
Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
|
Phase 3 | |
Withdrawn |
NCT01160055 -
Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children
|
N/A | |
Completed |
NCT00370227 -
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT00390910 -
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
|
Phase 3 | |
Completed |
NCT00985751 -
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination
|
Phase 2 | |
Withdrawn |
NCT01031329 -
Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey
|
N/A | |
Completed |
NCT00307554 -
A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study
|
Phase 3 | |
Completed |
NCT02270944 -
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
|
Phase 2 | |
Completed |
NCT01235949 -
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
|
Phase 4 | |
Completed |
NCT00985465 -
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali
|
Phase 3 | |
Completed |
NCT00861380 -
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
|
Phase 3 | |
Completed |
NCT01545375 -
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
|
Phase 2 |